BACKGROUND: Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) and an ejection fraction (EF) that has improved over time. This study ...

Discover the life-extending approaches to managing heart failure through medication adherence, lifestyle modifications, and ...

Heart failure is a serious, chronic condition. While medication can help the heart recover and improve its function, this study suggests that the medications themselves may continue to protect the ...

Patients who have been treated for heart failure and experience an improvement in their pump function are still at higher ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

For example, someone with a new diagnosis of heart failure may start on a low dose of ARNI and beta-blocker, and within a few days or weeks, add a mineralocorticoid antagonist and SGLT2 inhibitor ...

If ARNI use us not feasible and the patient is ... was evaluated in the Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial, leading to the ...

In patients with acute heart failure, it is unclear how body mass index affects clinical outcomes following acute myocardial infarction.

“Our results show that heart failure medications continue to provide ... “This supports the current recommendation to continue with RASi/ARNi and MRA treatment, but also opens up the ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.